S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

• John Mascarenhas,
• Tania Jain,
• Salman Otoukesh,
• Aaron T. Gerds,
• Alessandro Lucchesi,
• Iberia Romina Sosa,
• Kamel Laribi,
• Elena Mishchenko,
• Atanas Radinoff,
• Giulia Benevolo,
• Alessandro M. Vannucchi,
• Francoise Boyer,
• Philippe Quittet,
• Markus Radsak,
• Antoine Machet,
• Prithviraj Bose,
• Zhuying Huang,
• Hope Qamoos,
• Jesse Mcgreivy,
• Wayne P. Rothbaum,
• Srdan Verstovsek,
• Francesco Passamonti

Affiliations

John Mascarenhas

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States

Tania Jain

2 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, United States

Salman Otoukesh

3 City of Hope National Medical Center, Duarte, United States

Aaron T. Gerds

4 Cleveland Clinic Taussig Cancer Institute, Cleveland, United States

Alessandro Lucchesi

5 Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

Iberia Romina Sosa

6 Fox Chase Cancer Center, Philadelphia, United States

Kamel Laribi

7 Centre Hospitalier du Mans, Le Mans, France

Elena Mishchenko

8 Lady Davis Carmel Medical Center, Haifa, Israel

Atanas Radinoff

9 University Hospital Sveti Ivan Rilski, Sofia, Bulgaria

Giulia Benevolo

10 Haematology U Città della Salute e della Scienza, Turin, Italy

Alessandro M. Vannucchi

11 CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms University of Florence, Florence, Italy

Francoise Boyer

12 Centre Hospitalier Universitaire (CHU) d’Angers, Angers, France

Philippe Quittet

13 Centre Hospitalier Universitaire (CHU) Montpellier - Hôpital Saint Eloi, Montpellier, France

Markus Radsak

14 Johannes Gutenberg-Universität Mainz, Mainz, Germany

Antoine Machet

15 Hôpital Bretonneau, CHRU Tours Service d’Hématologie Clinique, Tours, France

Prithviraj Bose

16 The University of Texas MD Anderson Cancer Center, Houston, United States

Zhuying Huang

17 Kartos Therapeutics, Inc., Redwood City, CA, United States

Hope Qamoos

17 Kartos Therapeutics, Inc., Redwood City, CA, United States

Jesse Mcgreivy

17 Kartos Therapeutics, Inc., Redwood City, CA, United States

Wayne P. Rothbaum

17 Kartos Therapeutics, Inc., Redwood City, CA, United States

Srdan Verstovsek

16 The University of Texas MD Anderson Cancer Center, Houston, United States

Francesco Passamonti

18 University of Insubria, Varese, Italy